07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Epixis, VBI Vaccines deal

VBI acquired Epixis for an undisclosed amount. VBI said the acquisition would complement its thermostable vaccine formulation technologies and allows the company to develop virus-like particle (VLP) vaccines using Epixis' eVLP program. Terms were not...
07:00 , Aug 25, 2011 |  BC Innovations  |  Targets & Mechanisms

More than one way to stop HCV

A French team led by Epixis S.A. has developed an HCV vaccine that triggers both a T cell response and broadly neutralizing antibodies in macaques. 1 Because of the ability to elicit both types of...
07:00 , Aug 18, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Adenovirus-based prime and virus-like particle (VLP)-based boost vaccine regimen for HCV An adenovirus-based prime and VLP-based boost vaccine regimen that produces...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

Epixis deal

Epixis said that an undisclosed U.S. biotech company has approached it with an acquisition offer. Epixis expects to disclose details next month. Epixis' hepatitis C virus-like particle (HCV-VLP) vaccine is in preclinical to treat and...